[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.

Today promises to be very important for the entire tech sector. Why? Shares of Cerebras will begin trading on the Nasdaq Exchange. Without exaggeration, this is the most important public debut in the semiconductor industry since Arm (ARM).

Cerebras appears to be coming public at the perfect time. The initial price range was revised upward against the backdrop of colossal demand from institutional investors — they speak of a 20-fold oversubscription. At the target range of $150-$160 per share, the capitalization of Cerebras closely approaches the $48.8 billion mark. Even more tantalizing, the company is expected to actually price at $185. 

Fundamentals

See More
  • Market Capitalization, $K 291,136,448
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 14,315 M
  • EBITDA $ 20,048 M
  • 60-Month Beta 0.26
  • Price/Sales 4.87
  • Price/Cash Flow 14.27
  • Price/Book 6.04

Options Overview Details

View History
  • Implied Volatility 29.51% (+1.34%)
  • Historical Volatility 20.02%
  • IV Percentile 83%
  • IV Rank 67.95%
  • IV High 34.22% on 02/05/26
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 34) 11.42 (6.18%)
  • Put/Call Vol Ratio 0.64
  • Today's Volume 2,260
  • Volume Avg (30-Day) 3,306
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 94,041
  • Open Int (30-Day) 82,746
  • Expected Range 173.54 to 196.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.52
  • Number of Estimates 5
  • High Estimate $2.58
  • Low Estimate $2.44
  • Prior Year $2.18
  • Growth Rate Est. (year over year) +15.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
180.00 +2.76%
on 05/05/26
205.30 -9.91%
on 04/17/26
-19.42 (-9.50%)
since 04/14/26
3-Month
180.00 +2.76%
on 05/05/26
212.71 -13.05%
on 02/18/26
-20.59 (-10.02%)
since 02/13/26
52-Week
134.13 +37.89%
on 05/15/25
212.71 -13.05%
on 02/18/26
+52.50 (+39.63%)
since 05/14/25

Most Recent Stories

More News
Buying CBRS Stock After the Cerebras IPO Is a Bet on Engineering Magic. That Same Magic Could Be the Kiss of Death.

The Cerebras IPO is the most significant debut in the semiconductor industry since Arm.

NVDA : 235.74 (+4.39%)
AZN : 184.96 (-1.47%)
AMD : 449.70 (+0.94%)
ARM : 228.50 (+3.30%)
GSK : 50.96 (-0.06%)
TSM : 417.72 (+4.48%)
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

Perioperative IMFINZI plus IMJUDO® (tremelimumab-actl) and neoadjuvant EV showed a statistically significant and clinically meaningful improvement in event-free survival and a favorable trend for overall...

AZN : 184.96 (-1.47%)
AZN.LN : 13,740.000 (-0.19%)
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech

Analysts have initiated bullish coverage of Aprea Therapeutics with price targets up to 6x current levels, citing the superior safety profile and $700M peak sales potential of its WEE1 inhibitor program...

AZN : 184.96 (-1.47%)
ZNTL : 4.09 (-4.44%)
ACRV : 1.9200 (unch)
SDGR : 12.62 (-1.02%)
APRE : 0.9410 (+6.93%)
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

AZN : 184.96 (-1.47%)
ABBV : 210.77 (+1.09%)
GSK : 50.96 (-0.06%)
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

ODAC overwhelming majority voted that TRUQAP plus abiraterone and ADT demonstrated a favorable benefit risk profile for patients based on the CAPItello-281 Phase III trial results ...

AZN : 184.96 (-1.47%)
AZN.LN : 13,740.000 (-0.19%)
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Option exercise triggers $25M payment to Pinetree.

AZN : 184.96 (-1.47%)
AstraZeneca results: Q1 2026

Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition

AZN : 184.96 (-1.47%)
AZN.LN : 13,740.000 (-0.19%)
AstraZeneca's Oncology Portfolio Hides a Dependency Wall Street Hasn't Priced In

Barchart Research What to Expect from AZN Earnings AZN Generated April 28, 2026 Current Price $186.68 EPS Estimate $$2.57 Consensus Rating Moderate Buy Average Move 2.64% AstraZeneca's Oncology Portfolio...

AZN : 184.96 (-1.47%)
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled...

AZN : 184.96 (-1.47%)
AZN.LN : 13,740.000 (-0.19%)
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients

AZN : 184.96 (-1.47%)
AZN.LN : 13,740.000 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 188.21
2nd Resistance Point 187.45
1st Resistance Point 186.21
Last Price 184.96
1st Support Level 184.21
2nd Support Level 183.45
3rd Support Level 182.21

See More

52-Week High 212.71
Last Price 184.96
Fibonacci 61.8% 182.69
Fibonacci 50% 173.42
Fibonacci 38.2% 164.15
52-Week Low 134.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.